Neuroprotective effects of baicalein in animal models of Parkinson's disease: A systematic review of experimental studies.
There is an increasing of reports describing the efficacy of neuroprotective small molecule in Parkinson's disease (PD) models. Ideally, the choice of pushing drug candidates to clinical trial should be based on an unbiased assessment of all available data. Systematic review uses a methodical approach to minimize the bias in the selection of studies for inclusion, providing a comprehensive understanding of the drug's effects on multiple animal models with different mechanism. To our knowledge, such assessments of baicalein, which is a candidate neuroprotective drug with efficacy in PD, have not been fully conducted. To provide a comprehensive understanding of baicalein's effects on different animal models with different mechanism by using a methodical approach to minimize the bias in the selection of studies. In this study, we used a systematic review method to comprehensively assess the efficacy of baicalein in animal PD models. By using electronic and manual search for the literatures, we identified studies describing the efficacy of baicalein in animal models of PD. We identified 16 studies describing the efficacy of baicalein in animal models of PD. The methodological quality of all preclinical trials is ranged from 2 to 5. 16 studies involved 4 main kinds of PD animal models. They are MPP+-induced, rotenone-induced, 6-OHDA-induced and acrolein-induced PD models, respectively. The protective effects of baicalein were studied mainly focusing on the anti-oxidative, anti-apoptotic, and anti-inflammatory action. Beyond that, there are 2 articles describing the effects of baicalein on neurotransmitter balance in the basal ganglia, and 2 articles reporting the effects in decreasing synuclein aggregation. The results demonstrated the neuroprotective effects of baicalein in PD experimental animals and analyzed the pharmacological mechanism. The information will be useful for the further development of baicalein into anti-PD agent and provide unbiased evidence for the conduct of clinical trials. In addition, such evaluation based on animal experiments can give us a general introduction to different animal models of PD, either guiding the further model tests, or avoiding the unnecessary replication.